ಠ_ರೃ♡ try 1ClickFB.com download facebook videos

Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer

Say and pronounce Dr. Siefker-Radtke On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Durvalumab FDA Approval for Bladder Cancer   FDA Approval of Durvalumab for Bladder Cancer   FDA Approval of Durvalumab for Advanced Bladder Cancer   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   The FDA Approval of Atezolizumab in Bladder Cancer   Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC   FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More   Dr. Black on Combinations with Durvalumab in Bladder Cancer   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC   Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer   FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer   Update on Durvalumab for Metastatic Bladder Cancer   Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More   FDA Approvals in NSCLC, Bladder Cancer, and Breast Cancer, and Death in CAR T-cell Therapy Trial   Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer   FDA Approval of Atezolizumab for Advanced Bladder Cancer   Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer   Durvalumab for Treatment of Advanced Bladder Cancer   Highlights of Durvalumab for Advanced Bladder Cancer   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   Breakthrough In Leukemia Treatment   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   Novartis Metastatic Breast Cancer Treatment   Dr. Powles on Durvalumab in Urothelial Cancer   Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer   Combination Trials in Advanced Bladder Cancer   FDA Approvals in CRC, Blood Cancer Detection Diagnostic, and Alopecia, and More   FDA Approvals in Breast Cancer and Melanoma, Disappointing Results in HNSCC, and More   FDA Approvals in CRC, Blood Diagnostic, and Alopecia, and More   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   FDA Approval in MZL, Delay in Immunotherapy Combos in NSCLC, and 2017 GI Symposium Highlights   FDA Approval in CLL, Recommendation in NSCLC, Missed Endpoint in GBM Study, and More   FDA Approval in Breast Cancer, Breakthrough Designations in AML and Bladder Cancer, and More   Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More   FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights   Bladder Cancer Recurrence Discovered Through New Urine Test   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   Dr. Blackwell on Neratinib in HER2+ Breast Cancer   'Our Cancer Drug Is For Rich Westerners, Not Poor Indians'   Frontline Atezolizumab for Advanced Bladder Cancer   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   FDA Approval of Brigatinib for ALK+ NSCLC   FDA Approvals in Hematologic Malignancies, sBLA Accepted in Multiple Myeloma, and More   FDA approves breakthrough CAR-T therapy for leukemia   Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer   FDA Approval in Lung Cancer, Promising Findings in Hodgkin Lymphoma, and More   Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC   Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC   Bradley C. Leibovich, M.D.: Urologist - Mayo Clinic   Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC   Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL   FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More   Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC   Dr. Al-Kali on FDA Approval of Enasidenib in AML   Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer   FDA Approval in AML, Priority Review Designation in NSCLC, and More   Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer   Niraparib Maintenance for Recurrent Ovarian Cancer   Dr. Black on Sequencing of Immunotherapy in Bladder Cancer   Dr. Reidy-Lagunes on FDA Approval of Telotristat Epitrate for Carcinoid Syndrome   FDA Approvals in ALL and Breast Cancer, Priority Reviews in CML and Follicular Lymphoma, and More   Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer   Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer   FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More   Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More   Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer   FDA Warns 14 Companies About Fake Cancer 'Cure' Products

Popular Today